

IPSEN POST-ENETS SYMPOSIUM

2024
04/13

Sat. 14:00-18:00



台北漢來大飯店6F 會議中心(群嘉閣)
台北市南港區經貿一路168號

Time	Topic	Speaker	Moderator
14:00-14:05	Opening	陳彥仰 醫師 高雄長庚醫院	
14:05-14:35	How We Incorporate ENETS Updates to Clinical Practice?	陳明晃 醫師 台北榮民總醫院	陳彥仰 醫師 高雄長庚醫院
14:35-15:05	SSA Treatments in Real-World	黃文冠 醫師 林口長庚醫院	謝佳訓 醫師 土城長庚醫院
15:05-15:20	Panel Discussion	ALL	
15:20-15:35	Coffee Break		
15:35-16:05	Experience Sharing on SSA Treatment of NET Patients in NTUH	楊卿堯 醫師 台大醫院	白禮源 醫師 中國附醫
16:05-16:35	What is the Optimal Strategy to Manage GEP-NET?	蔡慧珍 醫師 國衛院	陳立宗 醫師 高醫附醫
16:35-16:50	Panel Discussion	ALL	
16:50-17:05	Coffee Break		
17:05-17:35	2024 ENETS Highlight	Dr. John RAMAGE King's College London	陳立宗 醫師 高醫附醫
17:35-17:55	Panel Discussion	ALL	
17:55-18:00	Closing	陳立宗 醫師 高醫附醫	

註冊報名

加入行事曆

僅限醫療人員參加 | Non Promotional Event

SOMA_NET-TW-000202

教育
學分

台灣外科醫學會、台灣內科醫學會、
台灣消化系外科醫學會、台灣消化系醫學會、
台灣內視鏡外科醫學會、台灣消化系內視鏡醫學會、
中華民國癌症醫學會 學分申請中

報名
方式

請事先填寫報名表報名參加
聯絡人：0953987920 黃小姐



IPSEN
post-ENETS
Symposium

4/13 (Sat.)

SG/ MY/ TW and HK **17:05-17:35**



(and 16:05-16:35 pm TH time; and 18:05-18:35 pm KR time)

2024 ENETS highlights

SPEAKER

Dr. John RAMAGE

King's College London

MODERATOR

Dr. Li-Tzong Chen

Kaohsiung Medical University Hospital

Panel Discussion

SG/ MY/ TW and HK **17:35-17:55**

(and 16:35-16:55 pm TH time; and 18:35-18:55 pm KR time.)



JOIN THE MEETING

Limited to healthcare
professionals only

Ipsen in partnership with Taiwan NeuroEndocrine
Tumor Society presents the post-ENETS symposium.

Curriculum Vitae

Name :

Ming-Huang Chen MD., Ph.D.

Business Address :

No. 201, Section 2, Shih-Pai Rd, Taipei, 11217, Taiwan

Professional Experience :

2023-present, Director, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital

2021-present, Secretary General, Taiwan Oncology Society

2020-2023, Director of Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital

2017-2019, Attending physician, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2021, Professor, National Yang Ming Chiao Tung University, Taiwan

2017, Visitor, National Cancer Center, Tokyo, Japan

2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)

Education and medical Training :

<Education>

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

<Medical training>

2005-2008 Fellowship in Division of Hematology & Oncology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2002-2005 Residency, Department of Internal Medicine

2001-2002 Internship, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

Board Certification :

Board of Oncology

Board of Hematology

Board of the Internal Medicine

Board of Hospice care

Board of Bone Marrow Transplantation

Memberships :

Taiwan Oncology Society

The Society of Internal Medicine

American Society of Clinical Oncology

European Neuroendocrine Tumor Society

Study Experiences

IIT trial

1. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, **Chen MH.** Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. *Clin Cancer Res.* 2022 Oct 3;28(19):4248-4257.

2. Chen MH, et al. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial. *Medicine (Baltimore).* 2016 Jan;95(3):e2565.

3. Chen MH, et al. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects with Poorly Differentiated Neuroendocrine Carcinomas, *Oncologist.* 2020 May;25(5):e782-e788

Publications (only first author or corresponding author):

Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DSS, Wu CE, Lai JI, Chang PMH, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, **Chen MH.** *PRKDC*: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. *J Immunother Cancer.* 2020 Mar;8(1):e000485

Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JCH, **Chen MH**[#] and Chun-Nan Yeh[#]. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response.. Accepted by *Clinical & Translational Immunology*

Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST). Might Be a More Promising Immune Biomarker in Colorectal Cancer.: *Oncologist.* 2019 Dec;24(12):1534-1542.

Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. *Clin Cancer Res.* 2016 Aug 15;22(16):4225-35.

Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, **Chen MH***, **Yeh CN**. MET-ROn dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-ROn upregulation indicates worse prognosis for intra-hepatic cholangiocarcinoma patients. *Oncol Rep.* 2018 Sep;40(3):1411-1421.

Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, **Chen MH**. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. *Int J Biol Sci.* 2016 Nov 25;12(12):1523-1532.

Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. *Oncotarget.* 2015 Sep 15;6(27):23594-608.

Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. *Oncotarget.* 2014;5:2372-89.

Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. *Ann Surg Oncol.* 2013;20:616-24.

Chen MH, Lin KJ, Yang WLR, Kao YW, Chen TW, Chao SC, Chang PMH, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CYF. Gene Expression-Based Chemical Genomics Identifies Heat Shock Protein 90 Inhibitors as Potential Therapeutic Drugs in Cholangiocarcinoma. *Cancer.* 2013;119:293-303.

Chen MH, Yeh YC, ShyrYM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PMH, Liu CY, Chen MH, Hsiao M, Huang CYF. Expression of Gremlin 1 Correlates

with Increased Angiogenesis and Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. *Journal of Gastroenterology*. 2013;48:101-8.

Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. *PLoS One*. 2011;6:e27186.

Curriculum Vitae

Name: Wen-Kuan Huang

Education: 1999-2006, MD, School of Medicine, Chung Shan Medical College, Taichung, R.O.C.

2014-2020, PhD, Karolinska Institutet, Department of oncology-pathology, Sweden

Postgraduate Training:

Sep., 2007-Jul., 2010: Residentsip, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Jul., 2010-August 2012: Fellowship, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Affiliation:

September 2012-now: Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

September 2021-now: Physician scientist, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

February 2023-now: Associate professor, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Research of Interest: cancer metabolism, immune microenvironment, DNA damage repair Grants (Recent 3 years)

1.108-2314-B-182A-063 - microRNA-mediated gastric gastrointestinal stromal tumor imatinib resistance through regulation of mitochondrial metabolism.
2019/08/01~2020/07/31 (PI)

2.CMRPG3K172 the mechanism of miR-483-3p regulation of aerobic phosphorylation and imatinib drug response in gastrointestinal stromal tumors by inhibiting succinate dehydrogenase.2020/10/1~2022/9/30 (PI)

3.111-2314-B-182A-031- Analysis of microsatellite instability status and tumor immune microenvironment characteristics in gastric cancer. 2022/08/01 ~2023/07/31 (PI)

4.CMRPG3M2101 TIGIT antibody combined with PD-1 antibody in microsatellite instable gastric cancer. 2022/12/1-2023/11/30 (PI)

5.CMRPG3N0481 HIF1-alpha and circCSPF6/CPSF6 interaction promotes pancreatic cancer growth. 2023/07/01-2024/6/30 (PI)

Publications (Recent 3 years)

1.Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, Chang JW, See LC, **Huang WK***. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer- Associated Venous Thromboembolism. JAMA Netw Open. 2021 Feb 1;4(2):e2036304. (SCI ; IF=13.8 ; Medicine, General & Internal 15/169=8.8%)

2.**Huang WK**, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S*. ARHGAP25 Inhibits Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. Int J Biol Sci. 2021 Apr 2 (SCI ; IF=9.2 ; Biochemistry&Molecular biology 57/297=19.2%)

3.Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, **Huang WK***, Haglund F*. Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. Front Immunol. 2022 Jan 7;12:788959. (SCI ; IF=7.3 ; Immunology 24/162= 14.8%)

4.Chen DY, Liu JR, Tseng CN, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Hsieh IC, Chu PH, Chen JS, Wen-Cheng Chang J, **Huang WK***, See LC. Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies. JACC CardioOncol. 2022 Jun 21;4(2):223-234. (SCI, IF=11.1; Cardiology = 7.7%)

5.Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, **Huang WK***, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. Int J Biol Sci. 2023 May 21;19(9):2772-86. (SCI ; IF=9.2)

CURRICULUM VIATE

Name: Hui-Jen Tsai, M.D. PhD.

Institute: National Institute of Cancer Research, National Health Research Institutes

Department of Oncology, National Cheng Kung University Hospital

Address: No.367, Sheng Li Road, Tainan 70456, Taiwan R.O.C.

Tel: (O) 886-6-7000123 ext.65149

Fax : (O) 886-6-2083427

E-mail: hjtsai@nhri.org.tw

EDUCATION:

- 1989.9 - 1993.6 Bachelor. National Chiao Tung University, Hsinchu, Taiwan
- 1993.9 - 1998.6 M.D. Kaohsiung Medical University, Kaohsiung, Taiwan
- 2005.9 – 2014.7 PhD. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

POSTDOCTORAL TRAINING and EXPERIENCE

- 2020.10 - Associate Investigator, National Institute of Cancer Research, National Health Research Institutes
- 2019.9- 2019.10 Visiting observership, Department of Experimental Therapeutics and Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Japan
- 2015.10- 2020.9 Assistant Investigator, National Institute of Cancer Research, National Health Research Institutes
- 2011.1 - 2015-9 Attending Physician, National Institute of Cancer Research, National Health Research Institutes
- 2008.2 - 2010.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital.
- 2006.8 - 2008.1 Visiting Researcher, Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo
- 2003.8-2006.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University

- Hospital.
- 2001.8 - 2003.7 Chief Resident, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital
- 1998.8 - 2001.7 Residency training, Department of Internal Medicine, Kaohsiung Medical University Hospital
- 1997.6 - 1998.5 Internship, Kaohsiung Medical University Hospital

LICENSURE AND CERTIFICATION:

- 1998 National Medical Board of Republic of China
- 2001 Specialist of Internal Medicine, Taiwan, R.O.C.
- 2003 Specialist of Hematology, Taiwan, R.O.C.
- 2004 Specialist of Medical Oncology, Taiwan, R.O.C.

HOSPITAL APPOINTMENTS:

- 2020.10 – Attending Physician, Department of Oncology, National Cheng Kung University Hospital
- 2011.1 – 2020.9 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
- 2003.8 – 2010.7 Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital

MEMBERSHIPS:

- 2001 Taiwan Society of Internal Medicine.
- 2003 The Hematology Society of Taiwan.
- 2004 The Chinese Oncology Society.(R.O.C)
- 2008 The American Society of Hematology

Selected Publications:

1. Hsu HP, Chu PY, Chang TM, Huang KW, Hung WC, Jiang SS, Lin HY, **Tsai HJ**. Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway. ***Cancer Med.*** 2023 Jan;12(2):1588-1601.

2. Ichinose Y, Yang YH, **Tsai HJ**, Huang RY, Higashi T, Nishida T, Chen LT. Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan. ***Sci Rep***. 2022;12:22492.
3. Chang TM*, Chu PY*, Lin HY, Huang KW, Hung WC, Shan YS, Chen LT, **Tsai HJ**. PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation. ***J Biomed Sci*** 2022;29:92.
4. Brose M, Smit J, Lin CC, Tori M, Bowles D, Worden F, Shen DH, Huang SM, **Tsai HJ**, Alevizaki M, Peeters RP, Takahashi S, Rumyantsev P, Guan R, Babajanyan S, Ozgurdal K, Sugitani I, Pitoia F, Lamartina L. Multi-kinase inhibitors for the treatment of asymptomatic radioactive iodine-refractory differentiated thyroid cancer. Global, non-interventional study (RIFTOS MKI). *Thyroid* 2022 Aug 11. doi: 10.1089/thy.2022.0061. Online ahead of print.
5. Hsu HP, Chu PY, Chang TM, Huang KW, Hung WC, Jiang SS, Lin HY, **Tsai HJ**. Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway. ***Cancer Med***. 27 June 2022 publish online.
6. **Tsai HJ**, Hsiao CF, Chang JS, Chen LT, Chao YJ, Yen CJ, Shan YS. The prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors – A single-center experience. ***Front. Oncol***. 2021(Nov);11:741096.
7. Yang SR, Tsai MH, Hung CJ, Peng SL, Chiu NT, Huang YH, **Tsai HJ**. Anaplastic thyroid cancer successfully treated with radiation and immunotherapy: a case report. ***AACE Clinical Case Rep*** 2021;7: 299-302. (corresponding author)
8. Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, **Tsai HJ**. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. ***Sci Rep*** 2021;11:7881.
9. **Tsai HJ**, Hsiao HH, Hsu YT, Liu YC, Kao HW, Liu TC, Cho SF, Feng X, Johnston A, Bomalaski JS, Kuo MC, Chen TY. Phase I Study of ADI-PEG20 plus Low Dose Cytarabine for the Treatment of Acute Myeloid Leukemia. ***Cancer Medicine*** 2021 May;10(9):2946-2955.
10. **Tsai HJ**, Shiah HS, Chang JY, Su WC, Chiang NJ, Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. ***Sci Rep*** 2021;11:4834.
11. Chang TM, Chu PY, Hung WC, Shan YS, Lin HY, Huang KW, Chang JS, Chen LT, **Tsai HJ**. c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation. ***Cancer Sci*** 2021 Jan;112(1):243-253.

12. Lin CY, Chang JS, Huang SM, Hung CJ, Hung CL, Chang CT, Yang HR, Hsieh TC, Huang YH, **Tsai HJ**. Experience of Sorafenib Treatment in Differentiated Thyroid Cancer from Taiwan. *J Formosan Medical Association*. 2021;120:189-195.
13. **Tsai HJ**, Tai JJ, Chen LT, Wu MS, Yeh KH, Lin CW, Wang TE, Wang HP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. *Haematologica*. 2020 Jul;105(7):e349-e354
14. Lin WH,[#] Wu SY,[#] Yeh TK,[#] Chen CT, Song JS, Shiao HY, Kuo CC, Hsu T, Lu CT, Wang PC, Wu TS, Peng YH, Lin HY, Chen CP, Weng YL, Kung FC, Wu MH, Su YC, Huang KW, Chou LH, Hsueh CC, Yen KJ, Kuo PC, Huang CL, Chen LT, Shih C, **Tsai HJ**,* and Jiaang WT*. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors (GISTs) and Acute Myeloid Leukemia (AML). *J Med Chem*. 2019 Dec 26;62(24):11135-11150.
15. **Tsai HJ**, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TA, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multi-targeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. *Cancer Science* 2018;109(11): 3591-3601.
16. **Tsai HJ**, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A phase II study of arginine deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients. *Sci Rep*. 2017 Sep 12;7(1):11253.
17. Chen LT, Chen CT, Jiaang WT, Chen TY, Butterfield JH, Shih NY, Hsu JT, Lin HY, Lin SF, **Tsai HJ**. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of *c-KIT* driven myeloid leukemia. *Mol Cancer Ther* 2016;15:2323-2333.

2024 ENETS highlight

John Ramage

Professor John Ramage is a consultant physician in gastroenterology and hepatology, honorary consultant physician at the Institute of Liver Studies, King's College Hospital and is deputy lead clinician for King's Health Partners NET Centre which includes King's, Guys and St Thomas's, Kent Oncology Centre, and Hampshire Hospitals. Professor Ramage is deputy research director at Hampshire Hospitals Foundation Trust and is lead clinician for the Hampshire Collaboration for Health Research and Education. He is an advisory board member and is on the executive board of the European Neuroendocrine Tumour Society. He is a member of the EORTC Quality of Life Group, through which he pursues research into quality of life in cancers. His main research interest is in quality of life and symptoms scores in neuroendocrine tumours of the small bowel and liver. He has written over 200 peer-reviewed publications and was the corresponding author of the UK guidelines for NET <https://orcid.org/0000-0003-4824-6600>

He has reviewed all the recent ENETS guideline papers (2023). He is chief investigator for several UK and international studies and recently co-ordinated Hampshire Hospitals Foundation Trust input into the RECOVERY study for COVID-19. More recent research includes comparing UK NET incidence and survival with that from the SEER database.